DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury

Status:
Terminated

Trial end date:
2021-03-04

Target enrollment:

Participant gender:

Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2

Phase 2

Durect